Leadership & Pay ·
Rani Therapeutics Holdings, Inc. announced the appointment of Nicholas M. Maestas as Chief Financial Officer…
RANIRani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. announced the appointment of Nicholas M. Maestas as Chief Financial Officer, effective June 29, 2026, succeeding Svai Sanford. Mr. Maestas's compensation package includes a $500,000 annual base salary, a 75% target bonus, and a grant of 2,000,000 Class A common stock options under the 026 Equity Inducement Plan. The company's Board of Directors also approved a 2026 Equity Inducement Plan, reserving 5,500,000 shares for inducement awards. Rani Therapeutics Holdings, Inc. is a biotechnology company focused on developing oral delivery technologies for oral drug delivery systems.